Core Viewpoint - The performance of Fulejia, known as the "first stock in medical beauty masks," has significantly declined, with a notable drop in revenue and profit in the first half of 2025 [2][7]. Financial Performance Summary - Fulejia reported a revenue of 863.11 million yuan, a year-on-year decrease of 8.15% [3]. - The net profit attributable to shareholders was 229.66 million yuan, down 32.54% year-on-year [3]. - The net profit after deducting non-recurring gains and losses was 166.17 million yuan, a substantial decline of 48.66% [3]. - The net cash flow from operating activities was 161.63 million yuan, down 54.69% [3]. - Basic and diluted earnings per share were both 0.44 yuan, a decrease of 32.31% [3]. - Total assets decreased by 6.33% to 5.70 billion yuan, while net assets attributable to shareholders fell by 3.01% to 5.49 billion yuan [3]. Reasons for Revenue Decline - The company attributed the revenue decline to the optimization of offline channels and increased promotional expenses, which surged by 39.56% to 420 million yuan, accounting for 48.67% of revenue [4][16]. - R&D investment was only 23.33 million yuan, representing a mere 2.7% of revenue, indicating a heavy reliance on promotional spending rather than innovation [4][21]. Market Competition and Product Performance - Fulejia's medical device segment generated 238.29 million yuan, a significant drop of 48.07%, while the cosmetics segment saw a revenue increase of 29.95% to 624.82 million yuan [8][9]. - The competition in the cosmetics industry is intensifying, with major companies entering the medical beauty sector, leading to price wars [9][11]. Sales Channel Shift - The company is shifting its sales strategy from offline to online channels, with online sales contributing 80.50% of total revenue, a 47.11% increase year-on-year [14][15]. - Offline sales dropped significantly by 63.99%, now accounting for only 19.50% of total revenue [14]. Future Strategies - Fulejia plans to focus on expanding its product line in the medical device sector and enhancing brand development through sub-brand incubation and flexible marketing strategies [11][12]. - The company aims to increase its online presence and sales, although it has been criticized for its late transition to online channels [18][19]. R&D and Regulatory Challenges - Fulejia's R&D investment remains low compared to peers, with only 31 patents approved and limited medical device registrations [22]. - Recent regulatory changes may impact the classification of medical dressings, potentially affecting the company's product offerings [22].